These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The safety and efficacy of enfuvirtide therapy for HIV infection in patients with hemophilia: a case series. Polizzotto MN; Street AM; Wright E Clin Infect Dis; 2007 Aug; 45(4):e39-41. PubMed ID: 17638184 [TBL] [Abstract][Full Text] [Related]
6. Drug profile: enfuvirtide (Fuzeon, ENF, T-20). Pham PA Hopkins HIV Rep; 2003 May; 15(3):1-2. PubMed ID: 12809104 [No Abstract] [Full Text] [Related]
7. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor. Cervia JS; Smith MA Clin Infect Dis; 2003 Oct; 37(8):1102-6. PubMed ID: 14523775 [TBL] [Abstract][Full Text] [Related]
8. [Fusion inhibitor enfuvirtidE. Continuous virologic and immunologic response]. Schäfer B MMW Fortschr Med; 2005 Apr; 147 Spec No 1():31. PubMed ID: 16385869 [No Abstract] [Full Text] [Related]
9. Switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and safety at 24 weeks in a Montreal cohort. Talbot A; Machouf N; Thomas R; Marcotte S; Therrien R; Lessard B; Dufresne S; Lalonde R J Acquir Immune Defic Syndr; 2009 Jul; 51(3):362-4. PubMed ID: 19553775 [No Abstract] [Full Text] [Related]
10. [Fusion inhibitors. One year therapy with T-20--initial evaluation]. Goebel FD MMW Fortschr Med; 2004 Apr; 146 Spec No 1():42-3. PubMed ID: 15373046 [No Abstract] [Full Text] [Related]
11. [Enfuvirtide, mechanism of action and pharmacological properties]. Kapić E; Becić F; Zvizdić S Med Arh; 2005; 59(5):313-6. PubMed ID: 16134757 [TBL] [Abstract][Full Text] [Related]
12. [Clinical efficacy and tolerance of enfuvirtide (Fuzeon), new antiretroviral inhibitors of intracellular penetration of human immunodeficiency virus (HIV) type 1]. Raffi F Med Mal Infect; 2004 Sep; 34 Spec No 1():8-17. PubMed ID: 15742550 [TBL] [Abstract][Full Text] [Related]
13. FDA notifications. Enfuvirtide has new instructions. AIDS Alert; 2007 Apr; 22(4):44-5. PubMed ID: 17595723 [No Abstract] [Full Text] [Related]
14. Fusion inhibition--a major but costly step forward in the treatment of HIV-1. Tashima KT; Carpenter CC N Engl J Med; 2003 May; 348(22):2249-50. PubMed ID: 12773653 [No Abstract] [Full Text] [Related]
15. HIV infection--a new drug and new costs. Steinbrook R N Engl J Med; 2003 May; 348(22):2171-2. PubMed ID: 12773643 [No Abstract] [Full Text] [Related]
17. Enfuvirtide (T-20): potentials and challenges. Foy K; Juethner SN J Assoc Nurses AIDS Care; 2004; 15(6):65-71. PubMed ID: 15538017 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M; N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645 [TBL] [Abstract][Full Text] [Related]
19. [Strategies for combating resistances in HIV therapy--an exemplifying case]. Stoehr A MMW Fortschr Med; 2004 Apr; 146 Spec No 1():70-1. PubMed ID: 15373056 [No Abstract] [Full Text] [Related]
20. Acute hypersensitivity reaction to enfuvurtide upon re-challenge. Beilke MA Scand J Infect Dis; 2004; 36(10):778. PubMed ID: 15513412 [No Abstract] [Full Text] [Related] [Next] [New Search]